Introduction
============

Diabetes mellitus (DM) is classified into either a type 1 DM caused by destruction of beta cell of pancreas or a type 2 DM resulting from insulin resistance and relative insulin deficiency. Previously, most childhood DM patients belong to type 1, but recently there has been a dramatic increase of type 2 DM[@B1][@B2][@B3][@B4][@B5]. However, it is sometimes not easy to classify DM based on clinical features. There is an increasing tendency of several cases presenting with noninsulin dependence despite autoantibody positivity at the time of diagnosis i.e., type 1.5 DM, latent autoimmune diabetes (LAD) in youth, slowly progressive type 1 DM, or youth onset diabetes of maturity[@B6]. LAD patients had older age of disease onset, and their blood glucose was well controlled without insulin injection at the time of diagnosis, but can eventually progressed into insulin dependence within several years. This study was designed to evaluate the clinical characteristics of childhood DM according to classification as well as the clinical course of LAD that initially showed non-insulin dependence despite autoantibody positivity.

Materials and methods
=====================

This study was designed as a cross-sectional study. A total of 91 subjects who were diagnosed with DM and could be followed up at Dankook University Hospital, Cheonan, Korea between 2001 and 2015 were enrolled in the study. The subjects with fulminant diabetes, \<6 months of follow-up, no assessment of the autoantibody status at disease onset, or weakly positive autoantibody that became negative during follow-up were excluded. Subjects were classified into 3 groups: type 1 DM, LAD, and type 2 DM. Type 1 DM group included patients who needed absolute insulin treatment for survival either in the presence of one or more autoantibody positivity or whose initial serum c-peptide level was lower than 0.6 ng/mL[@B7]. Type 2 DM group included patients with no autoantibody positivity as well as no requirement of absolute insulin treatment. LAD group included patients with initial autoantibody positivity without absolute insulin requirement for survival initially or within several months after the diagnosis. The definition of LAD was originated and modified from the diagnosis of latent autoimmune diabetes in adult (LADA)[@B8]. Clinical characteristics such as age at diagnosis, follow-up duration, body mass index (BMI) Z-score, initial presence of diabetic ketoacidosis (DKA), and treatment modality were reviewed. Laboratory findings such as autoantibody status, hemoglobin A1c (HbA1c), fructosamine, serum c-peptide, and serum c-peptide/glucose ratio as well as clinical characteristics were compared among groups. Autoantibodies evaluated in the study included anti-glutamic acid decarboxylase (GAD) autoantibody using immunoradiometric assay (Immunotech, Marseille, France), anti-insulin autoantibody using enzyme immunoassay (Orgentec Diagnostika GmbH, Mainz, Germany), anti-islet cell autoantibody using indirect fluorescent assay (SCIMEDX, Denville, NJ, USA), and antityrosine phosphatase insulinoma-associated 2 (IA-2) autoantibody using radioimmunoassay (RSR limited, Cardiff, UK). In LAD, laboratory findings including autoantibody status, HbA1c, serum c-peptide levels and change of treatment modality were monitored during follow-up. In this study, we defined intensive insulin treatment as insulin injection of more than 3 times a day to control blood glucose. BMI Z-scores were derived from LMS values presented by 2007 Korean Growth Normogram[@B9]. The LMS parameters are the power in the Box-Cox transformation (L), the median (M), and the generalized coefficient of variation (S).

Mann-Whitney *U*-test, Kruskal-Wallis test, and chi-square test were used for statistics using IBM SPSS Statistics ver. 20.0 (IBM Co., Armonk, NY, USA). A *P*-value of \<0.05 was considered statistically significant.

The study was approved by the Institutional Review Board of Dankook University Hospital (DKUH 2016-02-018).

Results
=======

1. Demographics and characteristics of the study subjects
---------------------------------------------------------

Ninety-one patients were included in the study. Among these, 47 were males and 44 were females. The mean age at diagnosis of all subjects was 10.76±4.32 years, and mean follow-up duration was 3.92±3.08 years. Among all patients, 38 (41.8%) presented DKA at diagnosis. At diagnosis, HbA1c was 12.13±2.37%, and fructosamine was 559.03±194.98 µmol/L. Initial glucose was 378.43±198.56 mg/dL, initial serum c-peptide was 1.72±1.92 ng/mL, and serum c-peptide/glucose ratio was 0.008±0.014.

2. Comparison between the groups subdivided by the type of DM
-------------------------------------------------------------

Among 91 subjects, type 1 DM, LAD, and type 2 DM were 51 (56.0%), 7 (7.7%), and 33 (36.3%), respectively ([Table 1](#T1){ref-type="table"}). Age at diagnosis and BMI Z-scores were lower (age at diagnosis 8.61±4.16 years vs. 13.18±3.42 years vs. 13.59±2.49 years, respectively *P*\<0.001; BMI Z-scores -1.21±1.47 vs. 0.78±0.91 vs. 0.91±1.51, respectively, *P*\<0.001), and DKA was more common (70% vs. 14.3% vs. 6.2%, respectively, *P*\<0.001) at disease onset in type 1 DM than in other 2 groups. Serum c-peptide levels and serum c-peptide/glucose ratio were lowest in type 1 DM (serum c-peptide 0.52±0.45 ng/mL vs. 1.92±1.07 ng/mL vs. 3.62±2.02 ng/mL, respectively, *P*\<0.001; serum c-peptide/glucose ratio 0.001±0.002 vs. 0.009±0.012 vs. 0.017±0.019, respectively, *P*\<0.001), and fructosamine levels at diagnosis were highest in type 1 DM (639.28±188.05 µmol/L vs. 579.0±119.03 µmol/L vs. 462.14±210.98 µmol/L, respectively, *P*=0.009). HbA1c at diagnosis showed no significant difference among groups subdivided by the type of DM. Autoantibody positivity was 96% in type 1 DM, with GAD autoantibody as most common ([Fig. 1](#F1){ref-type="fig"}). The positivity of each autoantibody in type 1 DM showed no significant difference when compared by age at onset. At diagnosis, fructosamine levels showed a significant difference between type 1 DM and type 2 DM (639.28±188.05 µmol/L vs. 462.14±210.98 µmol/L, respectively, *P*=0.003), but they had no significant difference between type 1 DM and LAD (639.28±188.05 µmol/L vs. 579.0±119.03 µmol/L, respectively, *P*=0.471).

3. Percentage and titers of autoantibody positivity according to type of DM
---------------------------------------------------------------------------

Among patients with type 1 DM, 10 patients (19.6%) had only GAD autoantibody, and 5 patients (9.8%) and 2 patients (3.9%) had only insulin autoantibody and IA-2 autoantibody, respectively ([Fig. 1](#F1){ref-type="fig"}). Twelve patients (23.5%) had GAD and insulin autoantibodies and 18 patients (35.3%) had GAD and IA-2 autoantibodies. Two patients had 3 autoantibodies, of these, 1 had GAD, insulin and IA-2 autoantibodies and the other had GAD, islet cell and IA-2 autoantibodies. Among patients with LAD, 2 (28.6%) had only insulin autoantibody, 3 (42.9%) had 2 autoantibodies (1 had GAD and IA-2 autoantibodies and others had GAD and insulin autoantibodies). Two patients with LAD had 3 autoantibodies including GAD, islet cell and IA-2 autoantibodies. Percentage and titers of each autoantibody showed no significant difference between type 1 and LAD.

4. Clinical and laboratory findings of LAD
------------------------------------------

Seven patients were classified into LAD (7.7%), and their mean follow-up duration was 4.56 years. Three patients (42.9%) required intensive insulin treatment during follow-up ([Table 2](#T2){ref-type="table"}), and their mean duration from diagnosis to intensive insulin treatment was 3.67 years. HbA1C and serum c-peptide levels at the time of initiation of intensive insulin treatment were 9.43±0.93% and 1.37±1.36 ng/mL, respectively. Age at diagnosis, initial BMI Z-score, HbA1c, serum c-peptide, and serum c-peptide/glucose ratio showed no significant difference between with and without intensive insulin treatment groups. However, recent serum c-peptide/glucose ratio was lower in the group with intensive insulin treatment (0.003±0.005 vs. 0.071±0.086, *P*=0.057), without statistical significance. LAD patients showed increasing trend of HbA1c, and decreasing trend of serum c-peptide during follow-up ([Fig. 2](#F2){ref-type="fig"}).

Discussion
==========

DM is one of the most common chronic metabolic diseases in children and adolescents. Childhood DM can be classified into either a type 1 DM that is characterized by insulin deficiency due to pancreatic beta cell damage or a type 2 DM that is characterized by insulin resistance at the level of skeletal muscle, liver, and adipose tissue combined with various degrees of beta cell impairment[@B10]. Recently, the prevalence of both type 1 and type 2 DM in children has been increasing, with a dramatic increase in type 2 DM[@B1][@B2][@B3][@B4][@B5][@B11]. Type 2 DM patients typically have clinical features characterized by older age of onset, high BMI, low prevalence of diabetes ketoacidosis and presence of signs of insulin resistance (hypertension, acanthosis nigricans), as compared with type 1 DM patients[@B4][@B12][@B13]. However, it is sometimes difficult to classify the case with type 2 clinical phenotype despite the presence of autoantibody, therefore it is usually designated as LAD[@B14].

Several previous studies on LAD in adults described the condition as LADA[@B6][@B15][@B16] or slowly progressive insulin dependent DM[@B17].

The diagnosis of LADA was established if following criteria were satisfied: (1) the onset was more than 35 years of age, (2) any circulating islet cell specific autoantibody was detected, (3) insulin therapy was not indicated in the first 6 months after the diagnosis[@B8]. Because our study subjects were children and adolescents, we defined LAD as DM patients who did not require absolute insulin treatment for survival initially or within several months after the diagnosis despite autoantibody positivity. The prevalence of LADA was estimated at 2%--12% of all cases of diabetes[@B6]. In 2005, Palmer et al.[@B15] reported that LADA patients commonly have reactive T cells to islet antigens and share many genetic similarities with type 1 DM, therefore LADA is an autoimmune disease like type 1 DM. However, a recent study on LADA indicated that LADA shows intermediate features between type 2 and type 1 diabetes, and a gradual decline in autoantibody titer in LADA subjects requiring insulin within the first year from diagnosis, as compared to subjects not requiring insulin after 10 years of follow-up[@B18]. A pediatric population study showed 9.8% of subjects with clinical type 2 diabetes were autoantibody positive, and had evidence of insulin deficiency due to islet autoimmunity[@B19].

In this study, 7 patients had LAD, defined as type 2 clinical phenotype and autoantibody positivity at the onset of DM. In general, patients diagnosed as LAD or slowly progressive type 1 DM progressed to insulin deficiency and became insulin dependent DM. In our study, LAD patients had similar clinical and laboratory features as type 2 DM patients except autoantibody positivity, male predominance, and lower initial serum c- peptide. Among the LAD patients, 3 patients needed absolute intensive insulin treatment and were treated by multiple insulin injection therapy; another 2 patients could be managed by long acting basal insulin with oral hypoglycemic agent; and the remaining 2 patients were treated only by oral hypoglycemic agents during follow-up. In LAD, age at diagnosis, BMI Z-score, and initial and recent c-peptide/glucose ratio showed no significant differences between the group with intensive insulin treatment and the group without intensive insulin treatment, possibly due to the small number of patients included in this study. Recent serum c-peptide/glucose ratio was lower in the group with intensive insulin treatment (0.003±0.005 vs. 0.071±0.086, *P*=0.057), although it was not statistically significant.

Cho et el.[@B20] reported that if the c-peptide level is \<0.6 ng/mL at diagnosis, type 2 DM can be excluded; in addition, if c-peptide level is \>3.0 ng/mL, a type 1 DM diagnosis is unlikely. However, one case with LAD required intensive insulin treatment during follow-up despite initial c-peptide level of 3.57 ng/mL. Therefore, it is considered that regular evaluation of serum c-peptide is important in patients with LAD.

Lohmann et el.[@B21] reported that among LADA patients, those with multiple autoantibodies have the same features as patients with type 1 diabetes; and the combination of islet cell antibodies and GAD antibodies and high titer of GAD antibodies are characteristic of patients with insulin deficiency with the clinical features of type 1 diabetes. However, LAD patients included in our study showed no significant differences in autoantibody titer and the number of autoantibody between with and without intensive insulin treatment groups, possibly due to the small number of patients included and lack of assessment of the status of some autoantibodies.

Determining when to start insulin treatment in LAD or type 2 DM patients is difficult. Previous reports have indicated predictors of subsequent insulin treatment requirement in patients with type 2 diabetes[@B22][@B23]. Saisho et el.[@B23] reported that postprandial serum c-peptide to plasma glucose ratio is the best predictive marker for future insulin therapy and the best cutoff value was 0.0202 with 80.8% sensitivity and 63.3% specificity. In our study, LAD patients with intensive insulin treatment showed below 0.0202 serum c-peptide to plasma glucose ratio at start of insulin treatment, whereas, group with no intensive insulin treatment showed above 0.0202 serum c-peptide to plasma glucose ratio.

Several recent studies have focused on markers of long-term endogenous insulin production in patients with DM. Sonoda et el.[@B24] reported that insulin secretion and resistance strongly influences fasting plasma c-peptide, and insulin secretion affects 24-hour pooled urine c-peptide in type 2 DM. Hope et al.[@B25] reported time to insulin and age at diagnosis were the best predictors of long-term insulin production. But in our study, we were unable to identify predictors of intensive insulin treatment in patients with LAD or type 2 DM.

All LAD patients were male with significant differences, as compared with type 1 or type 2 patients. This might be attributed to small number of study subjects, and further study will be required to ensure that the male gender is actually predominant in LAD.

DM is an established risk factor for microvascular disease like nephropathy, retinopathy, neuropathy leading to end-stage renal disease, loss of visual acuity, limb amputations[@B26], and macrovascular disease like atherosclerosis[@B27] leading to coronary heart disease, myocardial infarction or ischemic stroke[@B28]. DM is associated with substantial premature death from vascular diseases, several cancers and infectious disease[@B29]. Patients with DM also have higher risk of psychiatric disorder like depression, anxiety, or eating disorder[@B30][@B31]. All of these complications contribute to the excess morbidity and mortality in patients with diabetes. Therefore, control of blood sugar level is important in patients with DM. In LAD patients, insulin treatment is likely to be necessary within several years, therefore it is important to distinguish LAD patients who need insulin treatment from type 2 DM patients.

This study has several limitations. First, the number of patients classified into LAD in the study was small. Second, we could not analyze some factors that might show characteristics of LAD such as family history and urine c-peptide levels.

In conclusion, evaluation of autoantibody levels in patients with DM is important for classification and management. Reevaluation of autoantibody levels may be necessary in patients with initial weakly positive autoantibody titer in the presence of type 2 DM phenotype. It is important to closely monitor patients with positive autoantibody and clinical features of type 2 DM due to the expected need for intensive insulin treatment within several years.

The present research was conducted by the research fund of Dankook University in 2015.
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###### Clinical and laboratory characteristics of the study subjects

![](apem-21-212-i001)

  Variable                                    Type 1          LAD             Type 2          *P*-value                   
  ------------------------------------------- --------------- --------------- --------------- ------------- ------------- -------------
  Total (n=91)                                51 (56.0)       7 (7.7)         33 (36.3)                                   
  Sex                                                                                                                     
   Male                                       25 (49.0)       7 (100.0)       15 (45.5)       0.027^\*^     0.013^\*^     0.011^\*^
   Female                                     26 (51.0)       0 (0.0)         18 (54.5)                                   
  Age at diagnosis (yr)                       8.61±4.16       13.18±3.42      13.59±2.49      \<0.001^\*^   \<0.009^\*^   0.917
  Follow-up duration (yr)                     4.45±3.27       4.56±3.76       3.12±2.79       0.149         0.834         0.344
  DKA at diagnosis (n=89)                                                                                                 
   Present                                    35 (70.0)       1 (14.3)        2 (6.2)         \<0.001^\*^   0.008^\*^     0.457
   Absent                                     15 (30.0)       6 (85.7)        30 (93.8)                                   
  BMI *Z-*score at diagnosis (n=83)           --1.21±1.47     0.78±0.91       0.91±1.51       \<0.001^\*^   0.001^\*^     0.416
  Initial glucose (mg/dL) (n=87)              461.89±202.89   298.71±140.30   270.66±137.65   \<0.001^\*^   0.035^\*^     0.654
  HbA1C at diagnosis (%) (n=88)               12.54±2.01      11.51±2.34      11.64±2.79      0.258         0.354         0.900
  Fructosamine at diagnosis (μmol/L) (n=42)   639.28±188.05   579.0±119.03    462.14±210.98   0.009^\*^     0.471         0.271
  Initial serum c-peptide (ng/mL) (n=88)      0.52±0.45       1.92±1.07       3.62±2.02       \<0.001^\*^   0.002^\*^     0.049^\*^
  Serum c-peptide/glucose ratio (n=84)        0.001±0.002     0.009±0.012     0.017±0.019     \<0.001^\*^   0.001^\*^     0.128
  pH at diagnosis (n=62)                      7.23±0.16       7.38±0.11       7.38±0.03       0.003\*       0.114         0.654
  Number of autoantibody                      1.63±0.63       2.0±0.82        0±0             \<0.001^\*^   0.301         \<0.001^\*^
  GAD Ab titer (U/mL) (n=79)                  42.97±83.82     63.19±118.07    0.36±0.23       \<0.001^\*^   0.787         0.002^\*^
  Insulin Ab titer (U/mL) (n=71)              6.95±11.02      11\. 8±14.06    1.79±1.63       0.027^\*^     0.546         0.089
  IA-2 Ab titer (U/mL) (n=62)                 36.95±120.66    8.5±10.97       0.39±0.08       \<0.001^\*^   0.857         0.011^\*^
  Initial treatment (n=92)                                                                                                
   None                                       0 (0)           0 (0)           1 (3.0)         \<0.001^\*^   \<0.001^\*^   0.483
   Insulin only                               51 (100.0)      2 (28.6)        5 (15.2)                                    
   Insulin and OHA                            0 (0)           3 (42.9)        8 (24.2)                                    
   OHA only                                   0 (0)           2 (28.6)        19 (57.6)                                   

Values are presented as number (%) or mean ± standard deviation.

LAD, latent autoimmune diabetes; DKA, diabetic ketoacidosis; BMI, body mass index; GAD, glutamic acid decarboxylase; IA-2, insulinoma-associated 2; HbA1c, hemoglobin A1c; OHA, oral hypoglycemic agent.

^\*^*P*\<0.05.

###### Clinical and laboratory characteristics and follow-up data of patients with latent autoimmune diabetes

![](apem-21-212-i002)

  Variable                                             Group 1   Group 2   *P*-value                                                                       
  ---------------------------------------------------- --------- --------- ----------- ------------- -------- -------- -------- ------------ ------------- -------
  Sex                                                  M         M         M                         M        M        M        M                          
  Age at diagnosis (yr)                                14.2      14.49     8.49        12.39±3.16    9.03     18.32    14.55    13.2         13.78±3.83    0.629
  Initial BMI Z-score                                  0.49      0.82      1.11        0.81±0.31     2.64     0.003    0.05     0.04         0.77±1.26     0.400
  Initial HbA1c (%)                                    9.9       13.1      8.4         10.47±2.4     9.2      14.2     13.8     12           12.3±2.28     0.400
  Initial serum c-peptide                              0.1       2.4       3.57        2.02±1.77     1.6      2        2.4      1.36         1.84±0.46     0.629
  Initial serum c-peptide/glucose ratio                0.005     0.011     0.0357      0.02±0.02     0.003    0.0057   0.0084   0.0034       0.005±0.002   0.629
  GAD Ab                                               \-        \+        \+                        \+       \+       \-       \+                         
  Islet cell Ab                                        N/A       \+        \+                        \-       \-       \-       N/A                        
  Insulin Ab                                           \+        \-        \-                        \-       \+       \+       \+                         
  IA-2 Ab                                              N/A       \+        \+                        \+       N/A      \-       N/A                        
  Follow-up duration (yr)                              11.68     1.36      6.09        6.38±5.17     4.38     0.91     1.88     5.66         3.21±2.19     0.400
  Initial treatment                                    Insulin   Met+LI    Met                       Met      Met+LI   Met+LI                              
  Insulin Recent treatment                             IIT       IIT       IIT                       Met      Met+LI   Met      Met+Gmp+LI                 
  Time to insulin treatment (yr)                       7.64      0.66      2.7         3.67±3.59                                                           
  HbA1c at insulin treatment (%)                       9.7       8.4       10.2        9.43±0.93                                                           
  Serum c-peptide at insulin treatment (ng/mL)         0.1       2.8       1.2         1.37±1.36                                                           
  Serum c-peptide/glucose ratio at insulin treatment   0.0004    0.0156    0.0039      0.007±0.008                                                         
  Recent HbA1c                                         8.1       10.1      11.5        9.9±1.71      5.9      7.6      5.8      11.1         7.6±2.48      0.229
  Recent serum c-peptide                               0.1       1.9       0.1         0.7±1.04      4.1      3.13     20.4     1.85         7.37±8.74     0.114
  Recent serum c-peptide/glucose ratio                 0.0004    0.0083    0.0003      0.003±0.005   0.0339   0.0237   0.2      0.0253       0.071±0.086   0.057

Pt., patient; BMI, body mass index; HbA1c, hemoglobin A1c; GAD, glutamic acid decarboxylase; Ab, antibody; IA-2, insulinoma-associated 2; Met, metformin; Gmp, glimepiride; LI, long acting insulin; IIT, intensive insulin treatment; N/A, not assessed.
